Payment overview · 2025
General Payments
$1,547.83
82 reported records · 25 companies
Healthcare provider profile · identity verified
Todd Adam Halper, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ROCKVILLE CENTRE, NY · NPI 1518126655
Verified facts
What the public records show
CMS Open Payments records show Todd Adam Halper, M.D. received $1,547.83 in general payments during 2025 across 82 reported records.
ABBVIE INC. accounted for 23.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $370.73 | 23.9% | 24 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $128.23 | 8.3% | 5 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $111.25 | 7.2% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $94.03 | 6.1% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $92.93 | 6.0% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $89.06 | 5.8% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $78.98 | 5.1% | 4 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $61.78 | 4.0% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $60.43 | 3.9% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $58.52 | 3.8% | 3 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $49.85 | 3.2% | 3 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $39.05 | 2.5% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $38.86 | 2.5% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $36.26 | 2.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $32.63 | 2.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $29.02 | 1.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.81 | 1.5% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $22.60 | 1.5% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $22.56 | 1.5% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $21.39 | 1.4% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $20.14 | 1.3% | 1 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.60 | 1.1% | 1 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $17.43 | 1.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.45 | 1.1% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $14.24 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,547.83 | 82 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $259.02 | 17 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $236.64 | 17 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $134.09 | 7 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $128.23 | 5 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $111.25 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $94.03 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $89.06 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $78.98 | 4 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $61.78 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $60.43 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $59.80 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $58.73 | 3 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $49.85 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $48.60 | 3 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $40.29 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $39.28 | 2 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $39.05 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $39.05 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $39.05 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $38.86 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $36.26 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.20 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $32.63 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $29.02 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $29.02 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 95 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 122 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | 11 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
95 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
122 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 311 | 144 |
| Amlodipine Besylate | Amlodipine Besylate | 210 | 105 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 197 | 88 |
| Losartan Potassium | Losartan Potassium | 191 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 166 | 77 |
| Omeprazole | Omeprazole | 131 | 62 |
| Zolpidem Tartrate | Zolpidem Tartrate | 125 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 124 | 61 |
| Ozempic | Semaglutide | 122 | 34 |
| Alprazolam | Alprazolam | 110 | 41 |
| Metformin Hcl | Metformin Hcl | 101 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 101 | 41 |
| Simvastatin | Simvastatin | 99 | 39 |
| Azithromycin | Azithromycin | 96 | 70 |
| Mounjaro | Tirzepatide | 95 | 18 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 93 | 17 |
| Gabapentin | Gabapentin | 75 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 75 | 30 |
| Montelukast Sodium | Montelukast Sodium | 72 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 70 | 34 |
| Meloxicam | Meloxicam | 64 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 62 | 34 |
| Clonazepam | Clonazepam | 59 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 33 |
| Eliquis | Apixaban | 54 | 18 |
| Furosemide | Furosemide | 54 | 33 |
| Jardiance | Empagliflozin | 53 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 23 |
| Lisinopril | Lisinopril | 50 | 28 |
| Prednisone | Prednisone | 50 | 32 |
| Ezetimibe | Ezetimibe | 47 | 23 |
| Famotidine | Famotidine | 45 | 25 |
| Methylprednisolone | Methylprednisolone | 45 | 40 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 44 | 13 |
| Farxiga | Dapagliflozin Propanediol | 40 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 40 | 19 |
| Sertraline Hcl | Sertraline Hcl | 39 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 19 |
| Diazepam | Diazepam | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | 14 |
| Ramipril | Ramipril | 31 | suppressed |
| Xarelto | Rivaroxaban | 30 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 22 |
| Synthroid | Levothyroxine Sodium | 28 | 12 |
| Trazodone Hcl | Trazodone Hcl | 28 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 23 |
| Levofloxacin | Levofloxacin | 27 | 20 |
| Buprenorphine Hcl | Buprenorphine Hcl | 26 | suppressed |
| Carvedilol | Carvedilol | 26 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Potassium Chloride | Potassium Chloride | 25 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | 11 |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 23 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | 12 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 17 | 17 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Atenolol | Atenolol | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Ofloxacin | Ofloxacin | 14 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 11 |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,547.83 · 82 records | ABBVIE INC. | ACCRUFER, APLENZIN, APTIMA, AREXVY, Auvelity, BOTOX, BRIXADI, CAPVAXIVE, Cologuard Collection Kit, GARDASIL 9, GLYCATE, INSPIRE, JATENZO, Kerendia, Korlym, Leqembi, MOUNJARO, OTEZLA, Ozempic, QULIPTA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, REXULTI, SHINGRIX, SPRAVATO, SUBLOCADE, Saxenda, The Cologuard Plus Collection Kit, Tlando, UBRELVY, Wegovy, XYOSTED, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error